James R. Fuchs

James R. Fuchs's work spans medicinal chemistry and cancer biology, including the design of chemically modified natural-product compounds (semisynthetic derivatives) and studies of cell-signaling proteins involved in cancer progression, such as CD147 and STAT3 pathways in pancreatic cancer. The bibliographic record also includes tangential contributions related to computational chemistry (retrosynthesis prediction models) and topics like HIV drug development and curcumin-based therapeutics, suggesting a broad interest in drug discovery approaches. Prospective students would likely engage with a mix of organic synthesis, molecular biology, and possibly computational methods applied to therapeutic development.

Publication output was relatively steady and modest from 2017-2022 (2-10 per year), then spiked sharply in 2023 (51 outputs, largely supplementary materials tied to a single major study) before returning to a more typical range in 2024-2025.

Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026